Miconazolnitraat Teva (Miconazole Nitrate)

Miconazole nitrate blocks the fungal enzyme lanosterol 14α‑demethylase, which is essential for synthesising ergosterol, a key component of fungal cell membranes. Inhibiting this step disrupts membrane integrity, leading to increased permeability and fungal cell death at the site of application.

The specific dosing regimen for Miconazolnitraat Teva is determined by the prescribing healthcare professional based on the infection type, severity, and patient factors. The prescriber will provide instructions on the amount to apply, frequency, and duration of therapy.

Safety data for topical miconazole nitrate in pregnancy and lactation are limited. Healthcare providers usually weigh potential benefits against risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician before starting treatment.

To request Miconazolnitraat Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Miconazolnitraat Teva belongs to the imidazole class, offering broad‑spectrum activity against dermatophytes and yeasts. Compared with allylamine agents such as terbinafine, imidazoles have a slightly different mechanism and may be preferred for candidal infections. Choice of therapy depends on the pathogen, infection site and clinician preference.

Store Miconazolnitraat Teva at room temperature, below 25 °C, in its original container. Protect the product from moisture, excessive heat and direct sunlight to maintain stability and potency throughout its shelf life.

The product is applied topically to the affected skin area. Clean and dry the area before use, then spread a thin layer of the cream or ointment as directed by the prescriber, usually twice daily or as instructed, and wash hands after application.

Serious but rare risks include severe allergic reactions such as contact dermatitis, angioedema, urticaria, and, in exceptional cases, Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should stop use and seek immediate medical attention if they experience swelling, blistering, or widespread rash.

Individuals with a known hypersensitivity to miconazole nitrate or any component of the formulation should avoid using the product. It is also contraindicated on extensive broken skin or mucous membranes unless specifically prescribed by a healthcare professional.